Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05607953

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Locally Advanced Pancreatic Adenocarcinoma Clinical Trial

Official title:
A Phase 1/1b Pressure Enabled Regional Immuno-Oncology Study of Pancreatic Retrograde Venous Infusion of SD-101 Alone and With Checkpoint Blockade for Locally Advanced Pancreatic Ductal Adenocarcinoma

Clinical Trial Summary

This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.

Clinical Trial Description

This study will be conducted in 2 phases. In Phase 1, escalating doses of SD-101 will be administered alone via PRVI into the regional vessels of the pancreas containing the locally advanced tumor. The first three patients will part of a safety run-in. Following determination of the recommended MTD or optimal biologic dose (OBD) of SD-101 for PRVI, the study will progress to Phase 1b to assess the safety of concomitant SD-101 and CPI usage, along with preliminary efficacy. Patients in Phase 1b will receive the SD-101 dose selected from Phase 1 together with systemic anti-PD-1, defined as any FDA approved anti-PD-1, checkpoint blockade. SD-101 will be administered over 2 cycles, with 1 dose per cycle and each cycle being about 6 weeks apart. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05607953
Study type Interventional
Source TriSalus Life Sciences, Inc.
Contact Ann-Marie Hulstine
Phone 484-252-1960
Email annmarie.hulstine@trisaluslifesci.com
Status Recruiting
Phase Phase 1
Start date March 1, 2023
Completion date October 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05679674 - Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer N/A
Recruiting NCT04617821 - AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Phase 3
Completed NCT03673137 - Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC Phase 2/Phase 3
Recruiting NCT04652206 - Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. Phase 1/Phase 2
Completed NCT02394535 - Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer Phase 1
Not yet recruiting NCT06381154 - Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer Phase 2
Not yet recruiting NCT06399172 - OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
Withdrawn NCT03536182 - Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer Phase 3
Recruiting NCT04395469 - FAZA PET/MRI Pancreas N/A
Active, not recruiting NCT01585805 - Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Active, not recruiting NCT03269526 - BATs Treatment for Pancreatic Cancer, Phase Ib/II Phase 1/Phase 2
Recruiting NCT05524090 - PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
Completed NCT01342224 - Immunochemoradiotherapy in Patients With Pancreatic Cancer Phase 1
Completed NCT01278368 - Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection N/A
Recruiting NCT04172532 - Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer Phase 1/Phase 2
Active, not recruiting NCT04423731 - Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
Not yet recruiting NCT06272162 - Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy N/A
Active, not recruiting NCT00669734 - Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Phase 1
Recruiting NCT04665947 - First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer Early Phase 1
Recruiting NCT04570943 - Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Phase 2